Weihan Liu

Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute

SCHOLARLY PAPERS

1

DOWNLOADS

58

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Selective CDK7 Inhibition Has Dual Activity in Treatment Resistant Estrogen Receptor Positive Breast Cancer

Number of pages: 63 Posted: 20 Apr 2023
Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Massachusetts Institute of Technology (MIT) - Department of Biological Engineering, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Biomedical Informatics, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center - Center for Functional Cancer Epigenetics, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Baylor University - Lester and Sue Smith Breast Center, Azienda USL Toscana Centro - Bioinformatics Unit, Harvard University - Department of Oncologic Pathology, Harvard T.H. Chan School of Public Health - Department of Biostatistics, Baylor University - Department of Molecular and Cellular Biology, Harvard University - Lurie Family Imaging Center, Harvard University - Department of Oncologic Pathology, Azienda USL Toscana Centro - Sandro Pitigliani Translational Research Unit, Harvard University - Department of Cancer Biology, Harvard University - Department of Cancer Biology, Harvard University - Department of Data Science, Baylor University - Lester and Sue Smith Breast Center, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University - Department of Medical Oncology, Dana-Farber Cancer Institute and Independent
Downloads 58 (782,661)

Abstract:

Loading...

CDK7, breast cancer, ER positive, endocrine resistance, ESR1 mutant, CDK4/6 inhibitor resistance, Cell Cycle, CRISPR screen